Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies

Molecular Immunology

Volumn 48, Issue 6-7, 2011, Pages 860-866

  Wang, Weirong ^a   Vlasak, Josef ^a   Li, Yunsong ^a   Pristatsky, Pavlo ^a   Fang, Yulin ^a   Pittman, Tamara ^a   Roman, Jeanette ^a   Wang, Yang ^a,b   Prueksaritanont, Thomayant ^a   Ionescu, Roxana ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Sino Biological Inc   (China)

Author keywords

FcRn binding; Human FcRn mice; Methionine oxidation; Monoclonal antibody; Pharmacokinetics; Serum half life

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; METHIONINE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG HALF LIFE; DRUG STORAGE; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYDROGEN PEROXIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; MASS SPECTROMETRY; METHIONINE; MICE; OXIDATION-REDUCTION; PROTEIN BINDING; RECEPTORS, FC; SURFACE PLASMON RESONANCE; TIME FACTORS;

MUS; MUS MUSCULUS;

EID: 79951552251     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.12.009     Document Type: Article

References (29)

1. Bertolotti-Ciarlet A., Wang W., Lownes R., Pristatsky P., Fang Y., McKelvey T., Li Y., Li Y., Drummond J., Prueksaritanont T., Vlasak J. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol. Immunol. 2009, 46:1878-1882.
2. Gaza-Bulseco G., Faldu S., Hurkmans K., Chumsae C., Liu H. Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2008, 870:55-62.
3. Ghetie V., Ward E.S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol. 2000, 18:739-766.
4. Hermeling S., Crommelin D.J., Schellekens H., Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 2004, 21:897-903.
5. Hinton P.R., Xiong J.M., Johlfs M.G., Tang M.T., Keller S., Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 2006, 176:346-356.
6. Houde D., Peng Y., Berkowitz S.A., Engen J.R. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell Proteomics 2010.
7. Ionescu R., Vlasak J. Kinetics of chemical degradation in monoclonal antibodies: relationship between rates at the molecular and peptide levels. Anal. Chem. 2010, 82:3198-3206.
8. Jefferis R., Lefranc M.P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009, 1:332-338.
9. Kamei D.T., Lao B.J., Ricci M.S., Deshpande R., Xu H., Tidor B., Lauffenburger D.A. Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol. Bioeng. 2005, 92:748-760.
10. Keck R.G. The use of t-butyl hydroperoxide as a probe for methionine oxidation in proteins. Anal. Biochem. 1996, 236:56-62.
11. Lam X.M., Yang J.Y., Cleland J.L. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J. Pharm. Sci. 1997, 86:1250-1255.
12. Liu D., Ren D., Huang H., Dankberg J., Rosenfeld R., Cocco M.J., Li L., Brems D.N., Remmele R.L. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 2008, 47:5088-5100.
13. Liu H., Gaza-Bulseco G., Xiang T., Chumsae C. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. Mol. Immunol. 2008, 45:701-708.
14. Liu H., Gaza-Bulseco G., Zhou L. Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody. J. Am. Soc. Mass Spectrom. 2009, 20:525-528.
15. Martin W.L., West A.P., Gan L., Bjorkman P.J. Crystal structure at 2.8Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 2001, 7:867-877.
16. Ober R.J., Radu C.G., Ghetie V., Ward E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 2001, 13:1551-1559.
17. Pan H., Chen K., Chu L., Kinderman F., Apostol I., Huang G. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci. 2009, 18:424-433.
18. Petkova S.B., Akilesh S., Sproule T.J., Christianson G.J., Al Khabbaz H., Brown A.C., Presta L.G., Meng Y.G., Roopenian D.C. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 2006, 18:1759-1769.
19. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 2008, 20:460-470.
20. Qi P., Volkin D.B., Zhao H., Nedved M.L., Hughes R., Bass R., Yi S.C., Panek M.E., Wang D., Dalmonte P., Bond M.D. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J. Pharm. Sci. 2009, 98:3117-3130.
21. Raghavan M., Wang Y., Bjorkman P.J. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11200-11204.
22. Rao P.E., Kroon D.J. Orthoclone OKT3. Chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody. Pharm. Biotechnol. 1993, 5:135-158.
23. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7:715-725.
24. Sauerborn M., Brinks V., Jiskoot W., Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 2010, 31:53-59.
25. Shen, F.J., Kwong, M.Y., Keck, R.G., Harris, R.J., 1996. The Application of tert-Butylhydroperoxide Oxidation to Study Sites of Potential Methionine Oxidation in a Recombinant Antibody. Academic Press, Inc.
26. Suzuki T., Ishii-Watabe A., Tada M., Kobayashi T., Kanayasu-Toyoda T., Kawanishi T., Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 2010, 184:1968-1976.
27. Thirumangalathu R., Krishnan S., Bondarenko P., Speed-Ricci M., Randolph T.W., Carpenter J.F., Brems D.N. Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics. Biochemistry 2007, 46:6213-6224.
28. Wang S., Ionescu R., Peekhaus N., Leung J.-Yu., Ha S., Vlasak J. Separation of post-translational modifications in the Fc fragment of monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. J. Chromatogr. A 2010, 1217:6496-6502.
29. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 2010, 28:157-159.